{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T20:16:08Z","timestamp":1795292168024,"version":"4.10.3"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Once-daily, single-tablet regimens (STRs) have been associated with improved patient outcomes compared to multi-tablet regimens (MTRs). This study evaluated real world adherence and persistence of HIV antiretroviral therapy (ART), comparing STRs and MTRs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Adult Medicaid beneficiaries (aged\u2009\u2265\u200918\u00a0years) initiating ART with\u2009\u2265\u20092 ART claims during the identification period (January 1, 2015\u2013December 31, 2016) and continuous health plan enrollment for a 12-month baseline period were included. For STRs, the first ART claim date was defined as the index date; for MTRs, the prescription fill claim date for the last drug in the regimen was defined as the index date, and prescription fills were required to occur within a 5-day window. Adherence was assessed in 30-day intervals over a 6-month period, with adherence defined as having less than a 5-day gap between fills. Persistence was evaluated as median number of days on therapy and percent persistence at 12\u00a0months. Cox Proportional Hazard models were used to evaluate risk of discontinuation, controlling for baseline and clinical characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1,744 (STR\u2009=\u20091290; MTR\u2009=\u2009454) and 2409 (STR\u2009=\u20091782; MTR\u2009=\u2009627) patients newly prescribed ART had available data concerning adherence and persistence, respectively. Average age ranged 40\u201342\u00a0years. The patient population was predominantly male. Adherence assessments showed 22.7% of STR initiators were adherent to their index regimens over a 6-month period compared to 11.7% of MTR initiators. Unadjusted persistence analysis showed 36.3% of STR initiators discontinued first-line therapy compared to 48.8% for MTR initiators over the 2-year study period. Controlling for baseline demographic and clinical characteristics, MTR initiators had a higher risk of treatment discontinuation (hazard ratio [HR]\u2009=\u20091.6, p\u2009&lt;\u20090.0001). Among STRs, compared to the referent elvitegravir(EVG)\/cobicistat(COBI)\/emtricitabine(FTC)\/tenofovir alafenamide(TAF), risk of discontinuation was higher for efavirenz(EFV)\/FTC\/tenofovir disoproxil fumarate(TDF) (HR\u2009=\u20093.6, p\u2009&lt;\u20090.0001), EVG\/COBI\/FTC\/TDF (HR\u2009=\u20092.8, p\u2009&lt;\u20090.0001), and abacavir (ABC)\/lamivudine (3TC)\/dolutegravir (DTG) (HR\u2009=\u20091.8, p\u2009=\u20090.004). Among backbones, FTC\/TAF was associated with lower risk of discontinuation than FTC\/TDF (HR\u2009=\u20094.4, p\u2009&lt;\u20090.0001) and ABC\/3TC (HR\u2009=\u20092.2, p\u2009&lt;\u20090.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Among patients newly prescribed ART, STR initiators were significantly less likely to discontinue therapy and had greater adherence and persistence compared to MTR initiators. Regimens containing FTC\/TAF as a backbone had higher persistence than those consisting of other backbones.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12981-020-00268-1","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T09:02:49Z","timestamp":1585731769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries"],"prefix":"10.1186","volume":"17","author":[{"given":"Joshua","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Beaubrun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richa","family":"Bashyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieni","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Baser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,1]]},"reference":[{"key":"268_CR1","unstructured":"Statistics overview. Center of disease control and prevention. 2019. https:\/\/www.cdc.gov\/hiv\/statistics\/overview\/index.html. Updated 12 Apr 2019. Accessed 12 Aug 2019."},{"key":"268_CR2","unstructured":"Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. World Health Organization. 2016. http:\/\/www.who.int\/hiv\/pub\/arv\/arv-2016\/en\/. Accessed 12 Apr 2018."},{"issue":"1","key":"268_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","volume":"85","author":"S Broder","year":"2010","unstructured":"Broder S. The development of antiretroviral therapy and its impact on the HIV-1\/AIDS pandemic. Antiviral Res. 2010;85(1):1\u201318.","journal-title":"Antiviral Res"},{"issue":"42","key":"268_CR4","doi-asserted-by":"publisher","first-page":"e1677","DOI":"10.1097\/MD.0000000000001677","volume":"94","author":"PG Clay","year":"2015","unstructured":"Clay PG, Nag S, Graham CM, Narayanan S. Meta-analysis of studies comparing single and multi-tablet fixed dose combination HIV treatment regimens. Medicine. 2015;94(42):e1677.","journal-title":"Medicine"},{"issue":"1","key":"268_CR5","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12160-016-9827-3","volume":"51","author":"Y Chen","year":"2017","unstructured":"Chen Y, Chen K, Kalichman SC. Barriers to HIV medication adherence as a function of regimen simplification. Ann Behav Med. 2017;51(1):67\u201378.","journal-title":"Ann Behav Med"},{"key":"268_CR6","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. 2019. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/AdultandAdolescentGL.pdf. Accessed 15 Mar 2019."},{"key":"268_CR7","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDS Info. 2018. https:\/\/aidsinfo.nih.gov\/guidelines\/html\/1\/adult-and-adolescent-arv-guidelines\/11\/what-to-start. Accessed 12 Apr 2018."},{"issue":"2","key":"268_CR8","doi-asserted-by":"publisher","first-page":"e31591","DOI":"10.1371\/journal.pone.0031591","volume":"7","author":"PE Sax","year":"2012","unstructured":"Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS ONE. 2012;7(2):e31591.","journal-title":"PLoS ONE"},{"issue":"2","key":"268_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1037\/0278-6133.19.2.124","volume":"19","author":"SL Catz","year":"2000","unstructured":"Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAuliffe TL. Patterns, correlates, and barriers to medication adherence among persons prescribed new treatments for HIV disease. Health Psychol. 2000;19(2):124\u201333.","journal-title":"Health Psychol"},{"issue":"3","key":"268_CR10","first-page":"168","volume":"14","author":"JM Llibre","year":"2012","unstructured":"Llibre JM, Clotet B. Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. AIDS Rev. 2012;14(3):168\u201378.","journal-title":"AIDS Rev"},{"issue":"1","key":"268_CR11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10461-011-0082-0","volume":"17","author":"EC Ing","year":"2013","unstructured":"Ing EC, Bae JW, Maru DS, Altice FL. Medication persistence of HIV-infected drug users on directly administered antiretroviral therapy. AIDS Behav. 2013;17(1):113\u201321.","journal-title":"AIDS Behav"},{"key":"268_CR12","unstructured":"HIV drug chart. POZ. https:\/\/www.poz.com\/drug_charts\/hiv-drug-chart. Accessed 12 Apr 2018."},{"key":"268_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2147\/PPA.S192735","volume":"13","author":"F Altice","year":"2019","unstructured":"Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Patient Prefer Adherence. 2019;13:475\u201390.","journal-title":"Patient Prefer Adherence"},{"key":"268_CR14","first-page":"570316","volume":"2015","author":"B Armstrong","year":"2015","unstructured":"Armstrong B, Chan DJ, Stewart MJ, Fagan D, Smith D. Single tablet regimen usage and efficacy in the treatment of HIV infection in Australia. AIDS Res Treat. 2015;2015:570316.","journal-title":"AIDS Res Treat"},{"issue":"4 Suppl 3","key":"268_CR15","doi-asserted-by":"publisher","first-page":"19777","DOI":"10.7448\/IAS.17.4.19777","volume":"17","author":"L Tarrier","year":"2014","unstructured":"Tarrier L, Kegg S. Who gets single tablet regimens (STR), and why? J Int AIDS Soc. 2014;17(4 Suppl 3):19777.","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"268_CR16","doi-asserted-by":"publisher","first-page":"e003028","DOI":"10.1136\/bmjopen-2013-003028","volume":"3","author":"CJ Cohen","year":"2013","unstructured":"Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US Medicaid population with HIV. BMJ Open. 2013;3(8):e003028.","journal-title":"BMJ Open"},{"issue":"2","key":"268_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/phar.1889","volume":"37","author":"SS Sutton","year":"2017","unstructured":"Sutton SS, Magagnoli J, Hardin JW. Odds of viral suppression by single-tablet regimens, multiple-tablet regimens, and adherence level in HIV\/AIDS patients receiving antiretroviral therapy. Pharmacotherapy. 2017;37(2):204\u201313.","journal-title":"Pharmacotherapy"},{"issue":"7","key":"268_CR18","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/09540121.2015.1009362","volume":"27","author":"CW Holtzman","year":"2015","unstructured":"Holtzman CW, Shea JA, Glanz K, Jacobs LM, Gross R, Hines J, et al. Mapping patient-identified barriers and facilitators to retention in HIV care and antiretroviral therapy adherence to Andersen\u2019s Behavioral Model. AIDS Care. 2015;27(7):817\u201328.","journal-title":"AIDS Care"},{"issue":"4 suppl 3","key":"268_CR19","doi-asserted-by":"publisher","first-page":"19537","DOI":"10.7448\/IAS.17.4.19537","volume":"17","author":"D Sweet","year":"2014","unstructured":"Sweet D, Song J, Zhong Y, Signorovitch J. Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment. J Int AIDS Soc. 2014;17(4 suppl 3):19537.","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"268_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jinf.2017.01.012","volume":"74","author":"JM Lewis","year":"2017","unstructured":"Lewis JM, Smith C, Torkington A, Davies C, Ahmad S, Tomkins A, et al. Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: a multicentre retrospective cohort study. J Infect. 2017;74(4):401\u20137.","journal-title":"J Infect"},{"issue":"9835","key":"268_CR21","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","volume":"379","author":"E DeJesus","year":"2012","unstructured":"DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379(9835):2429\u201338.","journal-title":"Lancet"},{"issue":"2","key":"268_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/QAI.0000000000001481","volume":"76","author":"T Davy-Mendez","year":"2017","unstructured":"Davy-Mendez T, Eron JJ, Zakharova O, Wohl DA, Napravnik S. Increased persistence of initial treatment for HIV infection with modern antiretroviral therapy. J Acquir Immune Defic Syndr. 2017;76(2):111\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"268_CR23","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1186\/s12879-019-3975-6","volume":"19","author":"SJ Snedecor","year":"2019","unstructured":"Snedecor SJ, Radford M, Kratochvil D, Grove R, Punekar YS. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: a systematic review and network meta-analysis. BMC Infect Dis. 2019;19(1):484.","journal-title":"BMC Infect Dis"},{"key":"268_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","volume":"18","author":"T Cihlar","year":"2016","unstructured":"Cihlar T, Fordyce M. Current status and prospects of HIV treatment. Curr Opin Virol. 2016;18:50\u20136.","journal-title":"Curr Opin Virol"},{"key":"268_CR25","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","volume":"361","author":"PE Sax","year":"2009","unstructured":"Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230\u201340.","journal-title":"N Engl J Med"},{"key":"268_CR26","unstructured":"General equivalence mappings: ICD-9-CM to and from ICD-10-CM and ICD-10-PCS. Centers for Medicare & Medicaid Service. 2009. https:\/\/www.cms.gov\/Medicare\/Coding\/ICD10\/downloads\/ICD-10_GEM_fact_sheet.pdf. Accessed 20 Dec 2017."},{"issue":"4","key":"268_CR27","first-page":"242","volume":"22","author":"SS Sutton","year":"2016","unstructured":"Sutton SS, Hardin JW, Bramley TJ, D\u2019Souza AO, Bennett CL. Single-versus multiple-tablet HIV regimens: adherence and hospitalization risks. Am J Manag Care. 2016;22(4):242\u20138.","journal-title":"Am J Manag Care"},{"issue":"8","key":"268_CR28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1089\/apc.2014.0076","volume":"28","author":"MA Levi-Minzi","year":"2014","unstructured":"Levi-Minzi MA, Surratt HL. HIV stigma among substance abusing people living with HIV\/AIDS: implications for HIV treatment. AIDS Patient Care STDs. 2014;28(8):442\u201351.","journal-title":"AIDS Patient Care STDs"},{"issue":"1","key":"268_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10461-015-1164-1","volume":"20","author":"SM Sweeney","year":"2016","unstructured":"Sweeney SM, Vanable PA. The association of HIV-related stigma to HIV medication adherence: a systematic review and synthesis of the literature. AIDS Behav. 2016;20(1):29\u201350.","journal-title":"AIDS Behav"},{"issue":"3","key":"268_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/09540120050042891","volume":"12","author":"MA Chesney","year":"2000","unstructured":"Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. AIDS Care. 2000;12(3):255\u201366.","journal-title":"AIDS Care"},{"issue":"4","key":"268_CR31","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1097\/QAI.0b013e31817bbe80","volume":"48","author":"AD Bardeguez","year":"2008","unstructured":"Bardeguez AD, Lindsey JC, Shannon M, Tuomala RE, Cohn SE, Smith E, et al. Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr. 2008;48(4):408\u201317.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"268_CR32","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/jac\/dkv083","volume":"70","author":"F Raffi","year":"2015","unstructured":"Raffi F, Yazdanpanah Y, Fagnani F, Laurendeau C, Lafuma A, Gourmelen J. Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database. J Antimicrob Chemother. 2015;70(7):2121\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"268_CR33","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/phar.1728","volume":"36","author":"S Scott Sutton","year":"2016","unstructured":"Scott Sutton S, Magagnoli J, Hardin JW. Impact of pill burden on adherence, risk of hospitalization, and viral suppression in patients with HIV infection and AIDS receiving antiretroviral therapy. Pharmacotherapy. 2016;36(4):385\u2013401.","journal-title":"Pharmacotherapy"},{"issue":"1","key":"268_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12981-018-0204-0","volume":"15","author":"PG Clay","year":"2018","unstructured":"Clay PG, Yuet WC, Moecklinghoff CH, Duchesne I, Tronczy\u0144ski KL, Shah S, et al. A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther. 2018;15(1):17.","journal-title":"AIDS Res Ther"},{"issue":"1","key":"268_CR35","first-page":"88","volume":"25","author":"A Kangethe","year":"2019","unstructured":"Kangethe A, Polson M, Lord TC, Evangelatos T, Oglesby A. Real-world health plan data analysis: key trends in medication adherence and overall costs in patients with HIV. J Manag Care Spec Pharm. 2019;25(1):88\u201393.","journal-title":"J Manag Care Spec Pharm"},{"key":"268_CR36","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.2147\/PPA.S207908","volume":"13","author":"DM Hines","year":"2019","unstructured":"Hines DM, Ding Y, Wade RL, Beaubrun A, Cohen JP. Treatment adherence and persistence among HIV-I patients newly starting treatment. Patient Prefer Adherence. 2019;13:1927\u201339.","journal-title":"Patient Prefer Adherence"},{"issue":"9","key":"268_CR37","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1093\/cid\/ciu046","volume":"58","author":"JB Nachega","year":"2014","unstructured":"Nachega JB, Parienti JJ, Uthman OA, Gross R, Dowdy DW, Sax PE, et al. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;58(9):1297\u2013307.","journal-title":"Clin Infect Dis"},{"issue":"14","key":"268_CR38","doi-asserted-by":"publisher","first-page":"e6275","DOI":"10.1097\/MD.0000000000006275","volume":"96","author":"DR Drozd","year":"2017","unstructured":"Drozd DR, Saag MS, Westfall AO, Mathews WC, Haubrich R, Boswell SL, et al. Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice. Medicine. 2017;96(14):e6275.","journal-title":"Medicine"},{"issue":"1","key":"268_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40121-014-0024-z","volume":"3","author":"N Astuti","year":"2014","unstructured":"Astuti N, Maggiolo F. Single-tablet regimens in HIV therapy. Infect Dis Ther. 2014;3(1):1\u201317.","journal-title":"Infect Dis Ther"},{"key":"268_CR40","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3851\/IMP2287","volume":"18","author":"I Jarrin","year":"2013","unstructured":"Jarrin I, Hern\u00e1ndez-Novoa B, Alejos B, Riera M, Navarro G, Bernardino JI, et al. Persistence of novel first-line antiretroviral regimes in a cohort of HIV-positive subjects, CoRIS 2008\u20132010. Antivir Ther. 2013;18:161\u201370.","journal-title":"Antivir Ther"},{"issue":"12","key":"268_CR41","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1097\/QAD.0000000000001541","volume":"31","author":"B Youn","year":"2017","unstructured":"Youn B, Shireman TI, Lee Y, Gal\u00e1rraga O, Rana AI, Justice AC, et al. Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries. AIDS. 2017;31(12):1697\u2013707.","journal-title":"AIDS"},{"issue":"3","key":"268_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/14787210.2017.1286736","volume":"15","author":"A Imaz","year":"2017","unstructured":"Imaz A, Podzamczer D. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. Expert Rev Anti Infect Ther. 2017;15(3):195\u2013209.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"10","key":"268_CR43","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/hiv.12664","volume":"19","author":"D Hagins","year":"2018","unstructured":"Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, et al. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Med. 2018;19(10):724\u201333.","journal-title":"HIV Med"},{"issue":"4","key":"268_CR44","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2018.8431","volume":"320","author":"MS Saag","year":"2018","unstructured":"Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society\u2013USA Panel. JAMA. 2018;320(4):379\u201396.","journal-title":"JAMA"}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00268-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12981-020-00268-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-020-00268-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T05:33:32Z","timestamp":1666244012000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-020-00268-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["268"],"URL":"https:\/\/doi.org\/10.1186\/s12981-020-00268-1","relation":{},"ISSN":["1742-6405"],"issn-type":[{"value":"1742-6405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,1]]},"assertion":[{"value":"14 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Since the study herein does not involve the collection, use, or transmittal of individual identifiable data, Institutional Review Board approval was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed and approved this manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JC and OB have no conflicts to disclose. AB is an employee of Gilead Sciences Inc, the study sponsor. RB, AH, and JL are employees of STATinMED Research, a paid consultant to the study sponsor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12"}}